Arrowhead Pharmaceuticals is set to compete with Ionis in treating severe hypertriglyceridemia (sHTG) using plozasiran, which benefits from a $215 million priority review voucher enabling a faster market launch. Phase III trials SHASTA-3 and SHASTA-4 demonstrate plozasiran reduces triglycerides by 79–81% with a favorable safety profile, including quarterly dosing and no liver fat or thrombocytopenia issues. Arrowhead's current financials rely on partner revenue and strategic investments in sHTG, with about $1.35 billion liquidity expected to fund operations until early 2028, though additional funding may be needed as expenses rise. Key risks include Ionis maintaining payer-preferred status and slow market adoption, while Arrowhead aims for $3–4 billion peak US sales with important launch milestones through 2027.
Arrowhead Pharmaceuticals is noted here with a $215 million priority review voucher supporting its plozasiran drug development. For readers following the health sector, here is Pluang's market snapshot as of Oct 03, 2026 05:51 WIB: out of 100 priced US health stocks, 39 rose and 61 fell. Notable movers include ClearPoint Neuro Inc (CLPT) at USD 10.99 with 100% buy order activity, Incyte Corporation (INCY) at USD 116.69 with 97% sell order activity, and Bio-Rad Laboratories (BIO) at USD 368.65 with balanced buy/sell activity.
Midnight's NIGHT token surged about 100% in a week to $0.05, boosting its market cap to around $800 million as the network advances private smart contracts and tokenized bank deposits. Developers gained easier access to mainnet smart-contract deploym...
Dell Technologies reported record Q2 revenues with a 160% increase in non-GAAP operating income and a 43% earnings per share surprise, driven by strong operational discipline and margin strength. AI server orders surged 988% year-over-year, with back...
OKB token traded around $120.25 with minimal weekly price change, reflecting a quiet market. The key development is a nearly 10% drop in deposits on X Layer, the Ethereum scaling chain powered by OKB, falling from $186.9 million to $168.3 million sin...
The U.S. Securities and Exchange Commission (SEC) has reportedly approved the first 3x leveraged Bitcoin and Ethereum exchange-traded funds (ETFs) for listing and trading on a U.S. exchange, marking the highest leverage ratio cleared for crypto ETFs ...
Starz Entertainment (STRZ) has achieved over 100% gains year-to-date, supported by improving business fundamentals and attractive valuation. The company recently raised its full-year earnings guidance and committed to deleveraging its balance sheet, ...
